| APO-AMILZIDE | Health Canada | 2009-9-17 | APO-AMILZIDE-Health Canada-2009-9-17 | OTTAWA - Health Canada is informing Canadians that Apotex, a prescription drug manufacturer, has voluntarily, as a precautionary measure, recalled selected lots of three health products currently on the Canadian market.
Selected lots of the following products have been voluntarily recalled by Apotex: APO-AMILZIDE (5-50mg), APO-MELOXICAM (7.5 & 15mg) and APO-RANITIDINE (75 & 150 mg).
APO-MELOXICAM is indicated for treatment of symptoms of rheumatoid arthritis and osteoarthritis in adults.
APO-RANITIDINE is indicated for treatment and prevention of problems associated with excess stomach acid.
APO-AMILZIDE is indicated for the maintenance therapy of patients with liver cirrhosis with fluid in the abdomen and swelling.
This information comes in light of Health Canada's ongoing inspections of Apotex manufacturing facilities in the Greater Toronto Area.
Health Canada is also working with Apotex to undertake a thorough review of their Good Manufacturing Practices.
Good Manufacturing Practices (GMPs) are standards designed to ensure an effective overall approach to product quality control and risk management.
|